Literature DB >> 9754034

Clinical trials among worker populations: the value and significance of anamnestic findings and clinical and instrumental tests for diagnosing work-related musculoskeletal disorders of the upper limbs (WMSDs).

F De Marco1, M G Ricci, D Bonaiuti.   

Abstract

The authors discuss the value and significance of symptoms in WMSDs, in view of the fact that the anamnestic threshold proposed in epidemiological investigations cannot be used as clinical and diagnosing criteria. Some useful clinical procedures are suggested for cases where there is a suspicion of musculoskeletal disorders of the cervical spine and upper limbs, bearing in mind that they are to be applied within the framework of health surveillance programmes undertaken by health care practitioners who are not specialists in orthopaedics, physiatrics or neurology. The recommendations for instrumental tests and specialist referrals are also discussed for the various disorders. The authors also provide flow charts for the diagnostic procedures pertaining to WMSDs. The appendix shows a sample patient chart illustrating the proposed procedures; it also permits the findings to be encoded so that they can be stored in a dedicated database. The codes for diagnosing WMSDs are also reported for the same epidemiological purposes.

Entities:  

Mesh:

Year:  1998        PMID: 9754034     DOI: 10.1080/001401398186333

Source DB:  PubMed          Journal:  Ergonomics        ISSN: 0014-0139            Impact factor:   2.778


  2 in total

1.  Active epidemiological surveillance of musculoskeletal disorders in a shoe factory.

Authors:  Y Roquelaure; J Mariel; S Fanello; J-C Boissière; H Chiron; C Dano; D Bureau; D Penneau-Fontbonne
Journal:  Occup Environ Med       Date:  2002-07       Impact factor: 4.402

2.  Prevalence of musculoskeletal disorders in subjects not exposed to biomechanical overload.

Authors:  Giulia Stucchi; Silvia Cairoli; Rossana Crapanzano; Stefano Basilico; Giuseppe Leocata; Natale Battevi
Journal:  Med Lav       Date:  2018-02-01       Impact factor: 1.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.